The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: A roundtable discussion

Journal of Endocrinological Investigation

Volumn 22, Issue 11 SUPPL. 1, 1999, Pages 35-41

  Schlumberger, M J ^a   Incerti, C ^b   Pacini, F ^c   Reiners, C ^d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Medical Clinical and Regulatory Affairs   (Netherlands)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Hypothyroidism; Iodine 131 whole body scanning; Recombinant human thyroid stimulating hormone (rhTSH); Serum Tg testing; Well differentiated thyroid cancer

Indexed keywords

ANTITHYROID AGENT; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RECOMBINANT PROTEIN; THYROGLOBULIN; THYROTROPIN;

BLOOD; HUMAN; REVIEW; SENSITIVITY AND SPECIFICITY; THYROID TUMOR; TUMOR RECURRENCE;

ANTITHYROID AGENTS; HUMANS; IODINE RADIOISOTOPES; NEOPLASM RECURRENCE, LOCAL; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN;

EID: 0033252399     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Meier C.A., Braverman L.E., Ebner S.A., Veronikis I., Daniels G.H., Ross D.S., Deraska D.J., Davies T.F., Valentine M., DeGroot L.J., Curran P., McEllin K., Reynolds J., Robbins J., Weintraub B.D. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (Phase I/II Study). J. Clin. Endocrinol. Metab. 1994, 78: 188.
2. Ladenson P.W., Braverman L.E., Mazzaferri E.L., Brucker-Davis F., Cooper D.S., Garber J.R., Wondisford F.E., Davies T.F., DeGroot L.J., Daniels G.H., Ross D.S., Weintraub B.D. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N. Engl. J. Med. 1997, 337: 888.
3. Haugen B.R., Pacini F., Heiners C., Schlumberger M., Ladenson P.W., Sherman S.I., Cooper D.S., Graham K.E., Braverman I.E., Skarulis M.C., Davies T.F., DeGroot L.J., Mazzaferri E.L., Daniels G.H., Ross D.S., Luster M., Samuels M.H., Becker D.V., Maxon H.R. III, Cavalieri R.R., Spencer C.A., McEllin K., Weintraub B.D., Ridgway E.C. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J. Clin. Endocrinol. Metab. (in press).
4. th ed., Philadelphia, Lippincott, p. 445-462, 1991.
5. Schneider A.B., Line B.R., Goldman J.M., Robbins, J. Sequential serum thyroglobulin determinations, 1311 scans and 1311 uptakes after triiodothyronine withdrawal in patients with thyroid cancer. J. Clin. Endocrinol. Metab. 1981, 53: 1199.
6. Schlumberger M.J., Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. 1998, 138: 249.
7. Dow K.H., Ferrell B.R., Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997, 7: 613.
8. Keating F.R. Jr., Parkin T.N., Selby J.B., Dickinson L.S. Treatment of heart disease associated with myxoedema. Progr. Cardiovasc. Dis. 1961, 3: 364.
9. Haupt M., Kurz A. Reversibility of dementia in hypothyroidism. J. Neurol. 1993, 240: 333.
10. Maini C.L., Sciuto R., Tofani A. Delayed thyroid-stimulating hormone suppression by L-thyroxine in the management of differentiated thyroid cancer [letter]. Eur. J. Cancer 1993, 29A: 2072.
11. Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 1994, 97: 418.
12. DeGroot L.J., Kaplan E.L., McCormick M., Straus F.H. Natural history, treatment and course of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 1990, 71: 414.
13. Hay I.D. Papillary thyroid carcinoma. Endocrinol. Metab. Clin. North Am. 1990, 19: 545.
14. Montenegro J., González O., Saracho R., Aguirre R., González Ó., Martínez I. Changes in renal function in primary hypothyroidism. Am. J. Kidney Dis. 1996, 27: 195.
15. Park S.-G., Reynolds J.C., Brucker-Davis F., Whatley M., McEllin K., Maxted D., Robbins J., Weintraub B.D. Iodine kinetics during I-131 scanning in patients with thyroid cancer: comparison of studies with recombinant human TSH (rhTSH) vs hypothyroidism. J. Nucl. Med. 1996, 37: 15.
16. Pacini F., Lari R., Mazzeo S., Grasso L., Taddei D., Pinchera A. Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin. Endocrinol. (Oxf.) 1985, 23: 405.
17. Pacini F., Pinchera A., Giani C., Grasso L., Baschieri L. Serum thyroglobulin concentrations and 1311 whole body scans in the diagnosis of metastases from differentiated thyroid carcinoma (after thyroidectomy) (rapid communication). Clin. Endocrinol. 1980, 13: 107.
18. Wartofsky L., Sherman S.I., Gopal J., Schlumberger M., Hay I.D. The use of radioactive iodine in patients with papillary and follicular thyroid cancer [Therapeutic controversy]. J. Clin. Endocrinol. Metab. 1998, 83: 4195.
19. Schlumberger M.J. Papillary and follicular thyroid carcinoma [Medical progress]. N. Engl. J. Med. 1998, 338: 297.
20. Rendl J., Grelle I., Reiners C. Assay characteristics and clinical efficacy of a new sensitive Tg-assay in follow-up of differentiated thyroid cancer. Nuklearmedizin 35: abstr A59, 1996.